1. Usefulness of Growth Differentiation Factor-15 Levels to Predict Diabetic Cardiomyopathy in Asymptomatic Patients With Type 2 Diabetes Mellitus.
- Author
-
Dominguez-Rodriguez, Alberto, Abreu-Gonzalez, Pedro, and Avanzas, Pablo
- Subjects
- *
PEOPLE with diabetes , *DIABETIC cardiomyopathy , *ECHOCARDIOGRAPHY , *BLOOD sampling , *ENZYME-linked immunosorbent assay - Abstract
Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that increased in patients with established type 2 diabetes mellitus (DM). Diabetic cardiomyopathy (DC), defined as left ventricular diastolic dysfunction (LVDD) in patients with type 2 DM in the absence of arterial hypertension, heart disease, or other heart disease, was assessed by GDF-15 levels in type 2 DM patients with and without DC. A total of 213 DM outpatients had blood samples drawn and on the same day (basal) underwent echocardiography and treadmill exercise testing. Plasma GDF-15 concentrations were measured by an enzymelinked immunosorbent assay (ELISA) at baseline. DC was diagnosed in the presence of LVDD, defined when early mitral valve flow velocity (E) and early diastolic lengthening velocity (E') ratio was E/E' ⩾15. The prevalence of DC was 21.13%. GDF-15 levels were higher in patients with DC compared with those without DC (5,273 [8,708.4] vs 2,812.66 [7,662.1] pg/ml, respectively, p <0.001). We assessed predictors of DC using multivariate regression analysis. GDF-15 (odds ratio 9.9; 95% confidence interval [3.9 to 24.5], p <0.001) was the unique independent predictor of DC. The results of receiver operating characteristic curve show that the cut-off point of 3,812 pg/ml of GDF-15 was indicative for DC (AUC = 0.83, sensitivity = 82.2% and specificity = 70.2%, p <0.0001). In conclusion, GDF-15 represents a useful and novel tool to screen DC in patients with type 2 DM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF